

# Antonio Frassoldati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8850294/publications.pdf>

Version: 2024-02-01

120  
papers

3,873  
citations

147801

31  
h-index

133252

59  
g-index

125  
all docs

125  
docs citations

125  
times ranked

6106  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.2	17
2	Definition of High-Risk Early Hormone-Positive HER2 <sup>-</sup> Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
3	Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 547-547.	1.6	3
4	Randomized phase III trial on trabectedin (ET-743) single agent versus clinician <sup>™</sup> s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5504-LBA5504.	1.6	5
5	Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study. <i>Clinical Breast Cancer</i> , 2021, 21, e489-e496.	2.4	11
6	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	4.2	27
7	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 12.	5.2	9
8	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	2.8	20
9	Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report. <i>Immunotherapy</i> , 2021, 13, 971-976.	2.0	4
10	The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma. <i>Cancers</i> , 2021, 13, 4355.	3.7	5
11	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	2.8	5
12	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021, 154, 21-29.	2.8	8
13	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	10.7	41
14	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2 <sup>-</sup> Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	1.4	0
15	Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers. <i>Breast Journal</i> , 2020, 26, 560-562.	1.0	0
16	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64.	2.0	33
17	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	2.4	5
18	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52

#	ARTICLE	IF	CITATIONS
19	<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	7.0	17
20	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 497-507.	10.7	196
21	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102927.	4.4	15
22	Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). <i>British Journal of Cancer</i> , 2020, 123, 26-32.	6.4	17
23	Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer. <i>Molecular Oncology</i> , 2020, 14, 2163-2175.	4.6	20
24	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020, 16, 1433-1439.	2.4	14
25	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271.	1.1	33
26	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. <i>Cancers</i> , 2019, 11, 1431.	3.7	7
27	The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, e501-e510.	2.4	11
28	Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke. <i>Oncology and Therapy</i> , 2019, 7, 83-91.	2.6	5
29	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	7.0	147
30	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
31	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019, 17, 207.	5.5	4
32	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	2.0	122
33	Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 504-504.	1.6	10
34	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 544-544.	1.6	6
35	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 474-485.	10.7	59
36	HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights. <i>Clinical Breast Cancer</i> , 2018, 18, e1133-e1139.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1101-1105.	1.3	55
38	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncology, The, 2018, 19, 249-256.	10.7	130
39	Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study. European Journal of Cardio-thoracic Surgery, 2018, 53, 1199-1204.	1.4	30
40	High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy. Scientific Reports, 2018, 8, 4371.	3.3	14
41	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget, 2018, 9, 15350-15364.	1.8	79
42	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Molecular Therapy - Nucleic Acids, 2018, 11, 485-493.	5.1	81
43	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). European Journal of Cancer, 2018, 99, 9-19.	2.8	10
44	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget, 2018, 9, 31877-31887.	1.8	4
45	Patient and Health Care Professional Perspectives: A Case Study of the Lung Cancer Integrated Care Pathway. International Journal of Integrated Care, 2018, 18, 7.	0.2	5
46	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLETT Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. Oncologist, 2017, 22, 648-654.	3.7	10
47	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 2017, 82, 237-246.	2.8	38
48	Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S56-S62.	1.3	3
49	Patients with NSCLC may display a low ratio of p.T790M activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget, 2017, 8, 86056-86065.	1.8	13
50	Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study. Cancer Medicine, 2016, 5, 3272-3281.	2.8	23
51	Current views on anthracycline cardiotoxicity. Heart Failure Reviews, 2016, 21, 621-634.	3.9	39
52	Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients. Ultrasound in Medicine and Biology, 2016, 42, 125-132.	1.5	14
53	Triple positive early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget, 2016, 7, 17932-17944.	1.8	33
54	Abstract OT3-02-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer. ERIGE Trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)., 2016, .		0

#	ARTICLE	IF	CITATIONS
55	A post-reaction regimen for CRC patients manifesting hypersensitivity to oxaliplatin : an effective alternative not to rule out an important option of treatment. <i>Annals of Oncology</i> , 2015, 26, vi41.	1.2	1
56	Multigene prognostic and predictive tests in Luminal breast cancer patients: relation between Mammaprint <sup>®</sup> results and nodal status in a retrospectively monocentric analysis. <i>Annals of Oncology</i> , 2015, 26, vi12.	1.2	0
57	Predictive value of bevacizumab -related hypertension and proteinuria in patients with mCRC in the real practice. <i>Annals of Oncology</i> , 2015, 26, vi49.	1.2	0
58	The impact of nutritional support in head and neck cancer patients treated with chemoradiation therapy. <i>Annals of Oncology</i> , 2015, 26, vi72.	1.2	0
59	Biosimilar epoetin alfa in the management of chemotherapy-induced anemia: results from ANEMONE observational study. <i>Annals of Oncology</i> , 2015, 26, vi121.	1.2	1
60	Absolute quantification of cell-free microRNAs in cancer patients. <i>Oncotarget</i> , 2015, 6, 14545-14555.	1.8	103
61	Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma. <i>American Journal of Case Reports</i> , 2015, 16, 424-429.	0.8	20
62	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pNO Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0136731.	2.5	11
63	Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists. <i>Future Oncology</i> , 2015, 11, 1181-1189.	2.4	0
64	Next Generation Sequencing mutational analysis in -Triple Positive- breast cancer. <i>Annals of Oncology</i> , 2015, 26, vi22.	1.2	0
65	Evaluation of Tumor Response after first line combined therapy (Bevacizumab plus chemotherapy) in unresectable liver metastases from colorectal cancer: predictive value of RECIST 1.1 and CHOI criteria in short-term follow-up. <i>Annals of Oncology</i> , 2015, 26, vi47.	1.2	0
66	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015, 20, 1001-1010.	3.7	85
67	Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. <i>Biomarker Research</i> , 2015, 3, 12.	6.8	80
68	Abstract P3-06-23: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer. , 2015, , .		0
69	Abstract 3964: How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer. , 2015, , .		0
70	Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1050-1057.	1.6	46
71	Multidisciplinary Approach in Advanced Case of nasal Esthesioneuroblastoma: a Case Report and Review of Literature. <i>International Journal of Health Sciences (IJHS)</i> , 2014, 2, .	0.0	0
72	Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120.	2.2	73

#	ARTICLE	IF	CITATIONS
73	Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. <i>Annals of Oncology</i> , 2013, 24, 398-405.	1.2	284
74	Synchronous Papillary Carcinoma and Hemangiopericytoma with Lung Metastases. <i>Case Reports in Otolaryngology</i> , 2013, 2013, 1-3.	0.2	0
75	Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1989-1995.	1.6	330
76	Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, e76-e78.	1.6	118
77	Ovarian Endometrioid Adenocarcinoma With a Yolk Sac Tumor Component in a Postmenopausal Woman: Case Report and Review of the Literature. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2012, 5, 31-32.	0.1	4
78	Gastrointestinal Stromal Tumors and Other Malignancies: a Case Series. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 634-637.	1.3	13
79	Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial. <i>Clinical Breast Cancer</i> , 2012, 12, 40-48.	2.4	115
80	Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2150-2157.	1.5	16
81	PD05-01: Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. , 2011, , .		1
82	GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. <i>Cytotherapy</i> , 2010, 12, 466-477.	0.7	59
83	Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy. <i>Cancer Research</i> , 2010, 70, 3718-3729.	0.9	226
84	Chapter 7. Mesenchymal Stromal/Stem Cells from Tissue Repair to Destruction of Tumor Cells. , 2010, , 141-158.		0
85	Abstract P5-12-05:9Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. , 2010, , .		0
86	The clinical relevance of endocrine therapy-induced changes in lipid metabolism in breast cancer patients. <i>Cancer Biology and Therapy</i> , 2009, 8, 1456-1458.	3.4	4
87	A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. <i>Annals of Oncology</i> , 2009, 20, 1193-1198.	1.2	70
88	0132 The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trials. <i>Breast</i> , 2009, 18, S51-S52.	2.2	3
89	Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 131-136.	2.5	12
90	5149 Randomized phase II trial of preoperative chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: results of the first step simon's design. <i>European Journal of Cancer</i> , Supplement, 2009, 7, 304.	2.2	0

#	ARTICLE	IF	CITATIONS
91	Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial.. Cancer Research, 2009, 69, 1093-1093.	0.9	4
92	Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer.. , 2009, , .		0
93	Phase II, randomized trial of preoperative epirubicin-paclitaxel+/-gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Research and Treatment, 2008, 110, 127-134.	2.5	19
94	Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial). Clinical Breast Cancer, 2008, 8, 192-194.	2.4	29
95	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial); Tj ETQq1 1 0z784314 12BT /Over	1.0	54
96	Letrozole Versus Letrozole plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized, Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB). Clinical Breast Cancer, 2008, 8, 97-100.	2.4	15
97	Pulmonary Strongyloidiasis Mimicking Cancer Symptoms. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 308-309.	1.3	3
98	Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives. Cancer Letters, 2007, 248, 175-185.	7.2	23
99	Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer. Breast Cancer Research, 2007, 9, .	5.0	0
100	Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective. Breast Journal, 2007, 13, 28-35.	1.0	54
101	P101 A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer. Breast, 2007, 16, S41.	2.2	0
102	Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. European Journal of Haematology, 2006, 77, 109-113.	2.2	7
103	Predictive Value of Biologic Parameters for Primary Chemotherapy in Operable Breast Cancer. Clinical Breast Cancer, 2005, 6, 315-324.	2.4	6
104	HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results. Clinical Breast Cancer, 2005, 6, 253-259.	2.4	20
105	Is there a benefit by the sequence anastrozole+formestane for postmenopausal metastatic breast cancer women?. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 107-109.	2.5	11
106	Prospective Study of Indolent Non-follicular Non-Hodgkin's Lymphoma: Validation of Gruppo Italiano Per Lo Studio Dei Linfomi ( GISL ) Prognostic Criteria for Watch and Wait Policy. Leukemia and Lymphoma, 2002, 43, 1933-1938.	1.3	8
107	Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. European Journal of Cancer, 2002, 38, 2279-2288.	2.8	14
108	Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. Journal of Clinical Oncology, 2002, 20, 638-646.	1.6	48

#	ARTICLE	IF	CITATIONS
109	Comparison of CMF (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) With a Rotational Crossing and a Sequential Intensification Regimen in Advanced Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 593.	1.3	10
110	P86 Epirubicin as a single agent in comparison to CMF in adjuvant therapy of stage I and II breast cancer. <i>European Journal of Cancer</i> , 1998, 34, S36.	2.8	0
111	Changes of biological features in breast cancer cells determined by primary chemotherapy. <i>Breast Cancer Research and Treatment</i> , 1997, 44, 185-192.	2.5	37
112	Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. <i>Annals of Oncology</i> , 1996, 7, 619-624.	1.2	70
113	ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GSL). <i>Leukemia and Lymphoma</i> , 1995, 17, 313-320.	1.3	18
114	Hairy Cell Leukemia: A Clinical Review Based on 725 Cases of the Italian Cooperative Group (ICGHCL). <i>Leukemia and Lymphoma</i> , 1994, 13, 307-316.	1.3	86
115	Long Term Results of Interferon Treatment in Hairy Cell Leukemia Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL). <i>Leukemia and Lymphoma</i> , 1994, 14, 457-464.	1.3	15
116	Should alpha interferon be used as primary treatment for hairy cell leukemia?. <i>Leukemia Research</i> , 1991, 15, 419-426.	0.8	9
117	Splenectomy after initial therapy with alpha-IFN in patients with hairy cell leukemia (HCL): a multicenter study by the Italian Cooperative Group for HCL. <i>Preliminary results. European Journal of Haematology</i> , 1990, 45, 29-31.	2.2	4
118	Free-from-Failure Survival in Hodgkin's Disease. <i>Acta Haematologica</i> , 1989, 82, 179-186.	1.4	0
119	Human lymphoblastoid interferon as initial therapy in hairy cell leukaemia: a multicentre study in non-splenectomized patients. <i>British Journal of Haematology</i> , 1989, 72, 54-56.	2.5	10
120	Bone marrow infiltration in hairy cell leukemia after interferon therapy detected by magnetic resonance imaging. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 209-213.	0.7	8